Electra Therapeutics (NASDAQ:ETRA) Director Carl Gordon Acquires 22,700 Shares of Company Stock

by · The Markets Daily

Electra Therapeutics, Inc. (NASDAQ:ETRA – Get Free Report) Director Carl Gordon acquired 22,700 shares of Electra Therapeutics stock in a transaction that occurred on Tuesday, November 10th. The stock was purchased at an average price of $8.45 per share, with a total value of $191,815.00. Following the transaction, the director owned 5,255,278 shares of the company’s stock, valued at $44,407,099.10. This trade represents a 0.43% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Electra Therapeutics Stock Down 2.8%

Shares of ETRA opened at $7.99 on Wednesday. Electra Therapeutics, Inc. has a twelve month low of $6.86 and a twelve month high of $15.50.

Electra Therapeutics News Roundup

Here are the key news stories impacting Electra Therapeutics this week:

  • Positive Sentiment: Director Carl Gordon, through OrbiMed Advisors, reported purchases totaling 92,116 shares across November 6, 9 and 10, at prices ranging from $7.85 to $8.45 per share. Repeated buying by a director may signal confidence in the company, although it does not guarantee future performance. SEC ownership filing
  • Neutral Sentiment: A report said short interest stood at zero shares as of November 10, with zero days to cover. That figure does not indicate meaningful reported short positioning, but it conflicts with the report’s description of a “significant increase,” making the short-interest update difficult to interpret.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on ETRA. HC Wainwright began coverage on Electra Therapeutics in a research note on Monday, October 26th. They issued a “buy” rating and a $30.00 price target on the stock. Evercore began coverage on Electra Therapeutics in a report on Tuesday, October 13th. They set an “outperform” rating and a $36.00 price objective on the stock. Wall Street Zen upgraded Electra Therapeutics to a “hold” rating in a research report on Saturday, September 26th. TD Cowen initiated coverage on Electra Therapeutics in a report on Tuesday, October 13th. They issued a “buy” rating for the company. Finally, Jefferies Financial Group assumed coverage on shares of Electra Therapeutics in a research report on Tuesday, October 13th. They set a “buy” rating and a $32.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Buy” and an average price target of $33.50.

Get Our Latest Report on Electra Therapeutics

Electra Therapeutics Company Profile

(Get Free Report)

Electra Therapeutics, Inc. (NASDAQ: ETRA) is a clinical-stage biotechnology company focused on developing antibody-based medicines for diseases driven by abnormal immune-cell activity. The company’s approach is designed to selectively eliminate or modulate disease-causing immune cells while preserving healthy immune function. Electra’s lead investigational product is ELA026, an antibody targeting SIRPα, a protein involved in immune-cell signaling. The company is evaluating ELA026 in immune-mediated diseases, including systemic sclerosis and other conditions in which macrophages and related immune cells may contribute to disease progression.

Recommended Stories